Targeted therapy with HDAC inhibitors and RARβ2 agonists can restore pivotal TSG expression and produce significant antitumour effects by promoting differentiation in cervical squamous cell carcinoma. The gene discussed is HDAC9; the disease is cervical squamous cell carcinoma.